Identification

Name
Dobutamine
Accession Number
DB00841  (APRD00122)
Type
Small Molecule
Groups
Approved
Description

A beta-1 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery.

Structure
Thumb
Synonyms
  • (+-)-4-(2-((3-(P-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol
  • 3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine
  • 4-{2-[3-(4-hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol
  • DL-Dobutamine
  • Dobutamin
  • Dobutamina
  • Dobutamine
  • Dobutaminum
  • rac-Dobutamine
  • Racemic-dobutamine
External IDs
46236 / 81929
Product Ingredients
IngredientUNIICASInChI Key
Dobutamine d-tartrate5D1IB9AI6J101626-66-8WZIUXGZIVZDXIG-WUUYCOTASA-N
Dobutamine hydrochloride0WR771DJXV49745-95-1BQKADKWNRWCIJL-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dobutamine 12.5mg/mlSolution12.5 mgIntravenousIvax Pharmaceuticals Incorporated1996-11-252015-10-26Canada
Dobutamine HydrochlorideInjection, solution400 mg/100mLIntravenousPhysicians Total Care, Inc.2007-06-13Not applicableUs
DOBUTamine Hydrochloride in DextroseInjection, solution100 mg/100mLIntravenousHospira, Inc.1993-10-19Not applicableUs
DOBUTamine Hydrochloride in DextroseInjection, solution400 mg/100mLIntravenousHospira, Inc.1993-10-19Not applicableUs
Dobutamine Hydrochloride in DextroseInjection100 mg/100mLIntravenousBaxter Laboratories1993-09-27Not applicableUs
Dobutamine Hydrochloride in DextroseInjection400 mg/100mLIntravenousBaxter Laboratories1993-09-23Not applicableUs
DOBUTamine Hydrochloride in DextroseInjection, solution200 mg/100mLIntravenousHospira, Inc.1993-10-19Not applicableUs
Dobutamine Hydrochloride in DextroseInjection200 mg/100mLIntravenousBaxter Laboratories1993-09-27Not applicableUs
Dobutamine Hydrochloride Injection-12.5mg/mlLiquid12.5 mgIntravenousNovopharm Limited1997-02-01Not applicableCanada
Dobutamine Hydrochloride Injection-12.5mg/mlLiquid12.5 mgIntravenousSanofi1997-05-211998-10-24Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DobutamineInjection, solution12.5 mg/mLIntravenousGeneral Injectables & Vaccines2014-11-10Not applicableUs
DobutamineInjection, solution, concentrate12.5 mg/mLIntravenousHospira, Inc.1993-11-29Not applicableUs
DobutamineInjection, solution12.5 mg/mLIntravenousPhysicians Total Care, Inc.2006-12-11Not applicableUs
DOBUTamineInjection, solution12.5 mg/mLIntravenousHospira, Inc.1995-02-16Not applicableUs
Dobutamine HydrochlorideInjection, powder, lyophilized, for solution12.5 mg/mLIntravenousGeneral Injectables & Vaccines2010-03-012016-11-04Us
International/Other Brands
Dobuject (Bayer) / Dobusafe (Claris) / Dobutamin (Sandoz) / Dobutan (Demo) / Dobutel (Novell) / Dobutil (Meizler) / Dopmin (Mylan Seiyaku) / Inotrex (Lilly)
Categories
UNII
3S12J47372
CAS number
34368-04-2
Weight
Average: 301.3801
Monoisotopic: 301.167793607
Chemical Formula
C18H23NO3
InChI Key
JRWZLRBJNMZMFE-UHFFFAOYSA-N
InChI
InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
IUPAC Name
4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol
SMILES
CC(CCC1=CC=C(O)C=C1)NCCC1=CC(O)=C(O)C=C1

Pharmacology

Indication

For inotropic support in the short- term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures

Structured Indications
Pharmacodynamics

Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the beta-adrenoceptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. Dobutamine acts primarily on beta-1 adrenergic receptors, with little effect on beta-2 or alpha receptors. It does not cause the release of endogenous norepinephrine, as does dopamine. Dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.

Mechanism of action

Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output.

TargetActionsOrganism
ABeta-1 adrenergic receptor
agonist
Human
UBeta-2 adrenergic receptor
agonist
Human
UAlpha-2 adrenergic receptorsNot AvailableHuman
UEstrogen receptor alphaNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination

In human urine, the major excretion products are the conjugates of dobutamine and 3-O-methyl dobutamine.

Half life

2 minutes

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Dobutamine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Dobutamine.Experimental
AcebutololAcebutolol may decrease the bronchodilatory activities of Dobutamine.Approved
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Dobutamine.Approved, Investigational
AlprenololAlprenolol may decrease the bronchodilatory activities of Dobutamine.Approved, Withdrawn
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Dobutamine.Illicit, Withdrawn
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Dobutamine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Dobutamine.Approved
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Dobutamine.Approved, Illicit
AtenololAtenolol may decrease the bronchodilatory activities of Dobutamine.Approved
AtomoxetineAtomoxetine may increase the hypertensive activities of Dobutamine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Dobutamine is combined with Atosiban.Approved, Investigational
BendroflumethiazideDobutamine may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Dobutamine.Withdrawn
BenzphetamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Benzphetamine.Approved, Illicit
Benzylpenicilloyl PolylysineDobutamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Betahistine.Approved
BetaxololBetaxolol may decrease the bronchodilatory activities of Dobutamine.Approved
BisoprololBisoprolol may decrease the bronchodilatory activities of Dobutamine.Approved
BopindololBopindolol may decrease the bronchodilatory activities of Dobutamine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Dobutamine.Experimental
BromocriptineBromocriptine may increase the hypertensive activities of Dobutamine.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Dobutamine is combined with Bucindolol.Investigational
BumetanideDobutamine may increase the hypokalemic activities of Bumetanide.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Dobutamine.Investigational
BupranololBupranolol may decrease the bronchodilatory activities of Dobutamine.Approved
CabergolineCabergoline may increase the hypertensive activities of Dobutamine.Approved
Calcium AcetateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Acetate.Approved
Calcium CarbonateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium lactate.Approved, Experimental, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium laevulateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium laevulate.Experimental
Calcium pangamateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Phosphate.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Dobutamine.Withdrawn
CarteololCarteolol may decrease the bronchodilatory activities of Dobutamine.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Dobutamine.Approved, Investigational
CaseinThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Casein.Approved
CeliprololCeliprolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
ChlorothiazideDobutamine may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorphentermineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Chlorphentermine.Illicit, Withdrawn
ChlorthalidoneDobutamine may increase the hypokalemic activities of Chlorthalidone.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Dobutamine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Dobutamine.Approved, Vet Approved
CloranololCloranolol may decrease the bronchodilatory activities of Dobutamine.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dobutamine.Approved
CyclopenthiazideDobutamine may increase the hypokalemic activities of Cyclopenthiazide.Experimental
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Dobutamine.Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Dobutamine.Approved
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Dobutamine.Experimental
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Dobutamine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Dopamine.Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Dobutamine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Dobutamine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Doxofylline.Approved
DronabinolDronabinol may increase the tachycardic activities of Dobutamine.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Dobutamine.Approved
EntacaponeThe metabolism of Dobutamine can be decreased when combined with Entacapone.Approved, Investigational
EpanololThe risk or severity of adverse effects can be increased when Dobutamine is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Ephedrine.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Dobutamine.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Dobutamine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Dobutamine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Dobutamine.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Dobutamine.Investigational
EsmololEsmolol may decrease the bronchodilatory activities of Dobutamine.Approved
Etacrynic acidDobutamine may increase the hypokalemic activities of Etacrynic acid.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Dobutamine is combined with Fenoterol.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Dobutamine is combined with Fenozolone.Experimental
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Dobutamine.Approved, Investigational, Vet Approved
FurosemideDobutamine may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Dobutamine.Experimental
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Dobutamine.Experimental
HydrochlorothiazideDobutamine may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideDobutamine may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Hydroxyamphetamine.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Dobutamine.Approved
IndapamideDobutamine may increase the hypokalemic activities of Indapamide.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Dobutamine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Dobutamine.Approved, Investigational
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Dobutamine.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Dobutamine.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Dobutamine.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Dobutamine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Isoprenaline.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Dobutamine.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Dobutamine.Approved
LinezolidLinezolid may increase the hypertensive activities of Dobutamine.Approved, Investigational
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Dobutamine.Experimental
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Dobutamine.Withdrawn
MefenorexThe risk or severity of adverse effects can be increased when Dobutamine is combined with Mefenorex.Experimental
MephentermineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Mephentermine.Approved
MepindololMepindolol may decrease the bronchodilatory activities of Dobutamine.Experimental
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Dobutamine.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Methamphetamine.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Dobutamine.Approved, Investigational
MethyclothiazideDobutamine may increase the hypokalemic activities of Methyclothiazide.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Dobutamine.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive activities of Dobutamine.Approved
MetolazoneDobutamine may increase the hypokalemic activities of Metolazone.Approved
MetoprololMetoprolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Dobutamine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Dobutamine.Approved
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Dobutamine.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dobutamine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Dobutamine.Approved
NabiloneNabilone may increase the tachycardic activities of Dobutamine.Approved, Investigational
NebivololNebivolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Dobutamine.Withdrawn
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Dobutamine.Approved
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Dobutamine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Dobutamine is combined with Nylidrin.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Dobutamine.Withdrawn
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Dobutamine.Investigational
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Dobutamine.Approved
OxprenololOxprenolol may decrease the bronchodilatory activities of Dobutamine.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Oxymetazoline.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Dobutamine.Approved
PenbutololPenbutolol may decrease the bronchodilatory activities of Dobutamine.Approved, Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Dobutamine.Approved
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Dobutamine.Withdrawn
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Dobutamine.Approved, Illicit
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Dobutamine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Dobutamine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Dobutamine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Dobutamine.Approved, Vet Approved, Withdrawn
PiretanideDobutamine may increase the hypokalemic activities of Piretanide.Experimental
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Dobutamine.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Dobutamine.Withdrawn
PolythiazideDobutamine may increase the hypokalemic activities of Polythiazide.Approved
PrazosinPrazosin may decrease the vasoconstricting activities of Dobutamine.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Dobutamine is combined with Prenalterol.Experimental
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Dobutamine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Dobutamine is combined with Procaterol.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Dobutamine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Pseudoephedrine.Approved
QuinethazoneDobutamine may increase the hypokalemic activities of Quinethazone.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Racepinephrine.Approved
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Dobutamine.Approved
RitodrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Ritodrine.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Dobutamine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Dobutamine.Approved, Investigational, Vet Approved
SilodosinSilodosin may decrease the vasoconstricting activities of Dobutamine.Approved
SotalolSotalol may decrease the bronchodilatory activities of Dobutamine.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Dobutamine.Approved
SynephrineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Dobutamine.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Dobutamine.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Dobutamine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Terbutaline.Approved
TertatololTertatolol may decrease the bronchodilatory activities of Dobutamine.Experimental
Testosterone PropionateThe metabolism of Dobutamine can be decreased when combined with Testosterone Propionate.Approved, Vet Approved
TetryzolineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Tetryzoline.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Dobutamine.Approved, Investigational
TolcaponeThe metabolism of Dobutamine can be decreased when combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Dobutamine.Approved
TorasemideDobutamine may increase the hypokalemic activities of Torasemide.Approved
TramazolineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Tramazoline.Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Dobutamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dobutamine.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Dobutamine is combined with Tretoquinol.Experimental
TrichlormethiazideDobutamine may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Dobutamine.Experimental
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Dobutamine.Approved
TyramineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Tyramine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Dobutamine.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Dobutamine.Approved
Food Interactions
Not Available

References

Synthesis Reference

R. R. Tuttle, J. Mills, DE 2317710 (1973). J. Mills, R. R. Tuttle, U.S. Patent 3,987,200 (1976).

US5442120
General References
Not Available
External Links
Human Metabolome Database
HMDB14979
KEGG Drug
D03879
KEGG Compound
C06967
PubChem Compound
36811
PubChem Substance
46505241
ChemSpider
33786
BindingDB
50325274
ChEBI
4670
ChEMBL
CHEMBL926
Therapeutic Targets Database
DAP000245
PharmGKB
PA449381
IUPHAR
535
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Dobutamine
ATC Codes
C01CA07 — Dobutamine
AHFS Codes
  • 12:12.08.08 — Selective Beta 1-adrenergic Agonists
  • 12:12.00 — Sympathomimetic (Adrenergic) Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingBasic ScienceCardiovascular System Disease / Drug-Related Side Effects and Adverse Reactions1
1, 2TerminatedTreatmentShock1
1, 2WithdrawnBasic ScienceCardiovascular Disease (CVD) / Congestive Cardiomyopathy / Congestive Heart Failure (CHF) / Heart Diseases1
2CompletedTreatmentAcute Lung Injury (ALI)1
2CompletedTreatmentHemodynamics Instability1
2CompletedTreatmentShock, Septic1
2RecruitingTreatmentCardiorenal Syndrome1
2RecruitingTreatmentSevere Traumatic Brain Injury With High Cerebral Pressure1
2, 3CompletedTreatmentHeart Failure, Unspecified1
2, 3CompletedTreatmentInfection NOS / Severe Sepsis / Shock, Septic1
2, 3Unknown StatusTreatmentShock, Cardiogenic / Shock, Septic1
3CompletedNot AvailableCirrhotic Cardiomyopathy / Liver Cirrhosis1
3CompletedTreatmentAcute Heart Failure (AHF)1
3Enrolling by InvitationTreatmentCardiorenal Syndrome1
3Not Yet RecruitingTreatmentShock, Cardiogenic1
3TerminatedDiagnosticTetralogy Of Fallot1
4Active Not RecruitingTreatmentArterial Hypotension1
4CompletedDiagnosticArterial Hypotension / Free Flap / Head and Neck Carcinoma / Oral Cancers1
4CompletedPreventionMitral Valve Stenosis With Incompetence or Regurgitation1
4Not Yet RecruitingTreatmentAcute Heart Failure (AHF)1
4RecruitingNot AvailableHealthy Volunteers / Heart Failure, Unspecified1
4RecruitingTreatmentAcute Coronary Syndromes (ACS) / Low Cardiac Output Syndrome / Pulmonary Edemas / Shock, Cardiogenic1
4SuspendedTreatmentHeart Failure, Unspecified1
4TerminatedDiagnosticAnginal Pain / Asthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD) / Coronary Artery Disease1
4Unknown StatusSupportive CareCardiovascular Disease (CVD)1
4Unknown StatusTreatmentHeart Failure, Unspecified1
4Unknown StatusTreatmentMicrocirculation / Severe Sepsis1
4Unknown StatusTreatmentSingle Ventricle Heart Disease After Fontan Surgery1
Not AvailableCompletedNot AvailableAcute Circulatory Failure1
Not AvailableCompletedPreventionDiastolic Dysfunction1
Not AvailableCompletedTreatmentC.Surgical Procedure; Digestive System / Perioperative/Postoperative Complications1
Not AvailableCompletedTreatmentHeart Failure With Preserved Ejection Fraction (HFpEF) / Left Ventricular Hypertrophy/Hypertension / Pulmonary Diseases1
Not AvailableCompletedTreatmentOptimal Tissue Perfusion1
Not AvailableCompletedTreatmentShock, Septic1
Not AvailableNot Yet RecruitingNot AvailableHeart Failure, Unspecified1
Not AvailableRecruitingDiagnosticDiabetes-Related Complications1
Not AvailableRecruitingPreventionArterial Hypotension1
Not AvailableRecruitingScreeningShock, Septic1
Not AvailableRecruitingTreatmentAcute Kidney Injury (AKI)1

Pharmacoeconomics

Manufacturers
  • Astrazeneca lp
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Marsam pharmaceuticals llc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Baxter healthcare corp
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous12.5 mg/mL
Injection, solution, concentrateIntravenous12.5 mg/mL
Injection, powder, lyophilized, for solutionIntravenous12.5 mg/mL
Injection, solutionIntravenous400 mg/100mL
InjectionIntravenous100 mg/100mL
InjectionIntravenous200 mg/100mL
InjectionIntravenous400 mg/100mL
Injection, solutionIntravenous100 mg/100mL
Injection, solutionIntravenous200 mg/100mL
SolutionIntravenous12.5 mg
LiquidIntravenous12.5 mg
SolutionIntravenous250 mg
Prices
Unit descriptionCostUnit
Dobutamine 12.5 mg/ml vial0.18USD ml
Dobutamine 250 mg-d5w 500 ml0.09USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)184-186J. Mills, R. R. Tuttle, U.S. Patent 3,987,200 (1976).
logP3.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0137 mg/mLALOGPS
logP2.97ALOGPS
logP2.62ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)10.14ChemAxon
pKa (Strongest Basic)9.27ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area72.72 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity88.39 m3·mol-1ChemAxon
Polarizability34.44 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9937
Blood Brain Barrier-0.7448
Caco-2 permeable+0.5305
P-glycoprotein substrateSubstrate0.7571
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.6336
CYP450 2C9 substrateNon-substrate0.7235
CYP450 2D6 substrateSubstrate0.6265
CYP450 3A4 substrateNon-substrate0.5296
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8231
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8827
Ames testNon AMES toxic0.7215
CarcinogenicityNon-carcinogens0.9306
BiodegradationNot ready biodegradable0.9256
Rat acute toxicity2.2261 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.828
hERG inhibition (predictor II)Inhibitor0.8367
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0009000000-72fe7c46458e5a5d842b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0udi-0409000000-f41b2ba5a7a16faab22e
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-052r-0900000000-5a6988f6f954cc4d5970
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4r-1900000000-3760790cd7d468deb65b
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4l-4900000000-8656459c9b16b99f096c
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-05n0-0900000000-b4956c2ea5a7aa86eb32
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0udi-0009000000-99dd6da8a1a7db9cdda3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0f79-0903000000-297b7061da4a9bff6e29
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4r-1900000000-a5825e1ad3ae4837917c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4l-3900000000-84358b5b309fe282e24e
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4l-8900000000-fbdc06bd7571ae3e38a5

Taxonomy

Description
This compound belongs to the class of organic compounds known as catecholamines and derivatives. These are compounds containing 4-(2-Aminoethyl)pyrocatechol [4-(2-aminoethyl)benzene-1,2-diol] or a derivative thereof formed by substitution.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
Benzenediols
Direct Parent
Catecholamines and derivatives
Alternative Parents
Phenethylamines / Aralkylamines / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids / Dialkylamines / Organopnictogen compounds / Organooxygen compounds / Hydrocarbon derivatives
Substituents
Catecholamine / Phenethylamine / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid / Aralkylamine / Monocyclic benzene moiety / Secondary aliphatic amine / Secondary amine / Organopnictogen compound / Organooxygen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
secondary amine, catecholamine (CHEBI:4670)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Junker V, Becker A, Huhne R, Zembatov M, Ravati A, Culmsee C, Krieglstein J: Stimulation of beta-adrenoceptors activates astrocytes and provides neuroprotection. Eur J Pharmacol. 2002 Jun 20;446(1-3):25-36. [PubMed:12098582]
  2. La Rosee K, Huntgeburth M, Rosenkranz S, Bohm M, Schnabel P: The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines. Pharmacogenetics. 2004 Nov;14(11):711-6. [PubMed:15564877]
  3. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE: The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005 Dec 6;46(11):2111-5. Epub 2005 Nov 4. [PubMed:16325050]
  4. Raddatz A, Kubulus D, Winning J, Bauer I, Pradarutti S, Wolf B, Kreuer S, Rensing H: Dobutamine improves liver function after hemorrhagic shock through induction of heme oxygenase-1. Am J Respir Crit Care Med. 2006 Jul 15;174(2):198-207. Epub 2006 Apr 20. [PubMed:16627864]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Tibayan FA, Chesnutt AN, Folkesson HG, Eandi J, Matthay MA: Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44. [PubMed:9279221]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Ruffolo RR Jr, Spradlin TA, Pollock GD, Waddell JE, Murphy PJ: Alpha and beta adrenergic effects of the stereoisomers of dobutamine. J Pharmacol Exp Ther. 1981 Nov;219(2):447-52. [PubMed:6270308]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissu...
Gene Name
ESR1
Uniprot ID
P03372
Uniprot Name
Estrogen receptor
Molecular Weight
66215.45 Da
References
  1. McRobb FM, Kufareva I, Abagyan R: In silico identification and pharmacological evaluation of novel endocrine disrupting chemicals that act via the ligand-binding domain of the estrogen receptor alpha. Toxicol Sci. 2014 Sep;141(1):188-97. doi: 10.1093/toxsci/kfu114. Epub 2014 Jun 13. [PubMed:24928891]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Raxworthy MJ, Youde IR, Gulliver PA: Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents. Xenobiotica. 1986 Jan;16(1):47-52. [PubMed:2868577]
  2. Yan M, Webster LT Jr, Blumer JL: Kinetic interactions of dopamine and dobutamine with human catechol-O-methyltransferase and monoamine oxidase in vitro. J Pharmacol Exp Ther. 2002 Apr;301(1):315-21. [PubMed:11907189]

Drug created on June 13, 2005 07:24 / Updated on December 10, 2017 17:18